{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T19:59:26Z","timestamp":1775851166428,"version":"3.50.1"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0142466","type":"journal-article","created":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T19:00:13Z","timestamp":1449082813000},"page":"e0142466","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":20,"title":["High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients"],"prefix":"10.1371","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct00212082","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Sing-Huang","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nur Sabrina","family":"Sapari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikael","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Loh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wee-Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Iau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaik Ahmad","family":"Buhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richie","family":"Soong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Chin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,12,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1634\/theoncologist.9-4-361","article-title":"Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications","volume":"9","author":"C Osborne","year":"2004","journal-title":"Oncologist"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1517\/17425250903510611","article-title":"Clinical implications of chemotherapy-induced tumor gene expression in human breast cancers","volume":"6","author":"SH Tan","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/00130404-200211000-00010","article-title":"Global gene expression changes during neoadjuvant chemotherapy for human breast cancer","volume":"8","author":"TA Buchholz","year":"2002","journal-title":"Cancer J"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/FPC.0b013e32831ebb5d","article-title":"Chemotherapy-induced tumor gene expression changes in human breast cancers","volume":"19","author":"SC Lee","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1158\/0008-5472.CAN-14-0092","article-title":"Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer","volume":"74","author":"YZ Jiang","year":"2014","journal-title":"Cancer Res"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-2407-10-101","article-title":"A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes","volume":"10","author":"D Fumagalli","year":"2010","journal-title":"BMC Cancer"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/FPC.0b013e328330a39f","article-title":"Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer","volume":"19","author":"SC Lee","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"AB Miller","year":"1981","journal-title":"Cancer"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nature13600","article-title":"Clonal evolution in breast cancer revealed by single nucleus genome sequencing","volume":"512","author":"Y Wang","year":"2014","journal-title":"Nature"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"M Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature09807","article-title":"Tumour evolution inferred by single-cell sequencing","volume":"472","author":"N Navin","year":"2011","journal-title":"Nature"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrc3261","article-title":"Intra-tumour heterogeneity: a looking glass for cancer?","volume":"12","author":"A Marusyk","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e51021","DOI":"10.1371\/journal.pone.0051021","article-title":"Alterations in EGFR and related genes following neo-adjuvant chemotherapy in Chinese patients with non-small cell lung cancer","volume":"8","author":"S Wang","year":"2013","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/sj.bjc.6602970","article-title":"Mutation of the PIK3CA oncogene in human cancers","volume":"94","author":"B Karakas","year":"2006","journal-title":"Br J Cancer"},{"key":"ref15"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"FM Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"ref17","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3010","article-title":"Cabozantinib (XL184) has activity in both soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) w\/ advanced solid tumors","volume":"29","author":"MS Gordon","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.535","article-title":"Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT)","volume":"30","author":"EP Winer","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1186\/bcr2857","article-title":"Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy","volume":"13","author":"YH Teng","year":"2011","journal-title":"Breast Cancer Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/1078-0432.CCR-08-1757","article-title":"Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy","volume":"15","author":"RK Kancha","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref21","unstructured":"Ehrich M, Hogg G, Pearce M. Low abundant mutation profiling in tumor samples using the Sequenom OncoCarta Panel (Sequenom Application Note 12\/11\/2008)."},{"key":"ref22","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2014.55.7876","article-title":"PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer","volume":"32","author":"S Loibl","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1200\/JCO.2014.55.2158","article-title":"PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer","volume":"33","author":"IJ Majewski","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref24","unstructured":"COSMIC. Catalogue of somatic mutations in cancer. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/cancer.sanger.ac.uk\/cancergenome\/projects\/cosmic\/\" xlink:type=\"simple\">http:\/\/cancer.sanger.ac.uk\/cancergenome\/projects\/cosmic\/<\/ext-link> (accessed 21st Sept 2015)"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1158\/0008-5472.CAN-07-6854","article-title":"An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer","volume":"68","author":"K Stemke-Hale","year":"2008","journal-title":"Cancer Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10549-012-2035-3","article-title":"Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers","volume":"134","author":"L Santarpia","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/carcin\/bgs232","article-title":"The rebel angel: mutant p53 as the driving oncogene in breast cancer","volume":"33","author":"D Walerych","year":"2012","journal-title":"Carcinogenesis"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1586\/era.12.85","article-title":"Breast cancer intratumor genetic heterogeneity: causes and implications","volume":"12","author":"CK Ng","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer","volume":"368","author":"SJ Dawson","year":"2013","journal-title":"N Engl J Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0142466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T05:18:51Z","timestamp":1599887931000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0142466"}},"subtitle":[],"editor":[{"given":"Christos","family":"Hatzis","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,12,2]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2015,12,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0142466","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,2]]}}}